687 results about "Adverse effect" patented technology

The systems, devices, and methods presented herein use a blood pump to obtain measurements of cardiac function. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as aortic pressure or motor current, then calculate and display one or more cardiac parameters and heart function parameters, such as left ventricular pressure, left ventricular end diastolic pressure, or cardiac power output. These parameters provide valuable information to a user regarding current cardiac function, as well as positioning and function of the blood pump. In some embodiments, the system can act as a diagnostic and therapeutic tool. Providing cardiac parameters in real-time, along with warnings about adverse effects and recommendations to support cardiac function, such as increasing or decreasing the volumetric flow rate of blood pumped by the device, administering pharmaceutical therapies, and / or repositioning the blood pump allow clinicians to better support and treat cardiovascular disease.

The present invention provides systems, methods, and devices for electroporation-based therapies (EBTs). Embodiments provide patient-specific treatment protocols derived by the numerical modeling of 3D reconstructions of target tissue from images taken of the tissue, and optionally accounting for one or more of physical constraints or dynamic tissue properties. The present invention further relates to systems, methods, and devices for delivering bipolar electric pulses for irreversible electroporation exhibiting reduced or no damage to tissue typically associated with an EBT-induced excessive charge delivered to the tissue.

A composition of a compound represented by FIGS. 1A-1E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGS. 1A-1E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGS. 1A-1E and avoiding adverse effects present with psychedelics or entactogens.

The present disclosure relates to a herbo-mineral kit for alleviating adverse effects of chemotherapy resulting into improved quality of life of patients. The herbo-mineral kit comprises a first container containing Padmakadi Ghrut (PDG) in a thick, viscous form; a second container containing Mouktikyukta Kamdudha Vati (MKD) in a solid dosage form; a third container containing Praval Pishti Vati (PPV) in a solid dosage form; and a fourth container containing Ananta vati in a solid dosage form. The herbo-mineral kit of the present disclosure can be used for alleviating adverse effects of chemotherapy such as nausea, vomiting, constipation, diarrhea, stomatitis, and skin discoloration in cancer treatment. Use of the herbo-mineral kit of the present disclosure may prove to be beneficial in all types of cancers and diseases for which chemotherapy is treatment of choice.

The invention relates to the technical field of post return support, in particular to a cancer surviver post return support system, which comprises a health state evaluation module, a post matching adjustment module, a working duration optimization module, a task load balancing module and a cooperative work scheduling module. According to the invention, through fusion analysis of health data and physiological parameters and evaluation standards of individual rehabilitation stages, post matching adjustment can accurately adapt to key ability indexes based on actual health states, so that adverse effects of a fixed post distribution mode on rehabilitation of survivors are avoided; daytime high-tolerance, moderate-load and low-tolerance time periods are divided according to the physical ability fluctuation trend, so that the task arrangement sequence can be matched with the real-time states of survivors, the situation that high-load tasks are concentrated in the low-tolerance time period is avoided, the work fitness is optimized, matching is conducted based on the post competency indexes of the members in the same group, the team task allocation strategy is optimized, and the task allocation efficiency is improved. And survivors can complete the adaptive task within the adaptive working duration.

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

A facemask and accessories which overcomes the adverse effects and limitations of current designs by moving the maxilla and mandible in forward direction, which assists in correcting maxillary and mandibular skeletal and dentoalveolar deficiency and help expand the upper airway by advancing the mandible. This is accomplished by a design that is supported only by forehead and produces forces in front of maxilla and mandible. The extra-oral facebow design is characterized by providing two independent force adjustments, one above the forehead and the other one in front of the face by attachments to the upper and lower jaw bones and teeth. In particular, the two independent adjustments are provided by a fully adjustable forehead pad and bilateral adjustable bows on opposite sides of the facebow's extra-oral frame to provide protracting forces.

The invention discloses a near-infrared fluorescent probe for detecting ONOO <-> as well as a preparation method and application of the near-infrared fluorescent probe, and belongs to the technical field of peroxynitroso ion detection. The near-infrared fluorescent probe for detecting ONOO <-> provided by the invention is high in detection speed, and the highest fluorescence intensity can be reached within 60 seconds; the reaction is obvious and easy to observe, when the compound reacts with ONOO <->, strong red fluorescence can be generated, and the change of the color of the solution can be observed by naked eyes; the selectivity is strong, the sensitivity is high, the interference of other biological molecules and active substances can be effectively avoided, the accuracy and the reliability of a detection result are ensured, and the lowest detection limit can reach 107nM; the hydrogel has good biocompatibility, is low in toxicity in a living body, and does not generate adverse effects on normal physiological functions of a biological sample; the provided preparation method is simple and easy to operate, the raw materials are low in cost and easy to obtain, the synthesis efficiency is high, and the preparation method can be used for large-scale industrial production and has wide application prospects.

Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

The invention relates to an implantable prosthesis device and an implantable prosthesis system, and relates to the technical field of medical instruments. The implantable prosthetic device includes: a first tubular member having a first lumen; a second tubular member having a second lumen; the first tubular component is connected with the second tubular component, and the second tubular component is partially contained in the first tubular cavity so that the outer wall of the second tubular component can be matched with the inner wall of the first tubular component to form a channel capable of being opened or closed. The channel is in an open state and is communicated with the first pipe cavity; when the first tubular component and the second tubular component are in the radial unfolding state, the channel is in the closed state. The implantable prosthesis device provided by the invention can keep the blood flow smooth in the operation process, and prevents the adverse effect on the health of a patient due to blood flow blockage.

Embodiments disclosed herein include methods and systems for managing outcomes for weight-loss GLP-1 receptor agonist therapies using biochemical data-trained models and / or other patient centric analysis. In some embodiments, one or more biomarkers or other patient data are employed for training AI / ML or other computational models and / or as inputs to AI / ML or other computational models to evaluate patient response to GLP-1 receptor agonist therapy. For example, the computational models may be configured to perform classifications with respect to success of GLP-1 receptor agonist therapy and / or adverse effects during GLP-1 receptor agonist therapy.

The invention belongs to the technical field of effusion drainage, and provides a peritonitis pleural effusion drainage device which comprises an effusion storage box and a puncture needle, the puncture needle is connected with the effusion storage box through a drainage tube, the interior of the effusion storage box is divided into an upper cavity and a lower cavity, and the cavity located on the lower side is divided into a first containing cavity and a second containing cavity which are arranged left and right; the liquid storage tank is provided with a first connecting pipe and a second connecting pipe which are respectively communicated with the first placing cavity and the second placing cavity, and the first connecting pipe and the second connecting pipe are respectively connected with a test tube and a flushing structure for extracting antibiotics; by arranging the speed regulating structure, adverse effects on a patient caused by too high ascites flow speed are avoided; by arranging the fixing cylinder, the end of the drainage tube and the liquid storage bag can be conveniently and firmly installed, and the situation that the liquid storage bag falls off during shaking, and environmental pollution is caused is avoided; a liquid outlet cover is arranged, so that medical workers can conveniently and quantitatively take out ascites for detection.

The invention discloses a high-utilization-rate ginseng active ingredient medicinal preparation and a preparation method thereof, and relates to the technical field of medicines. The high-utilization-rate ginseng active ingredient pharmaceutical preparation is prepared from chitosan coated drug-loaded porous silicon dioxide composite nanoparticles and a drug-loaded MIL-101 metal organic framework matrix material, chitosan-coated drug-loading porous silicon dioxide composite nanoparticles are loaded on the surface of a drug-loading MIL-101 metal organic framework base material, and sodium alginate and a chitosan gel material are subjected to cross-linking connection, so that independent coating is formed, the framework base material and the composite nanoparticles are connected into a whole, the encapsulation performance and the drug loading capacity are improved, and the drug-loading capacity of the drug-loading MIL-101 metal organic framework composite nanoparticles is improved. Furthermore, the loading and the loading stability of the ginsenoside are improved, the adverse effects of gastric juice and gastrointestinal peristalsis on the activity of the ginsenoside are effectively reduced, the release and the absorption of the ginsenoside in intestinal tracts are remarkably enhanced, and the bioavailability is relatively high.

The invention provides a preparation method and application of mesenchymal stem cell exosomes, and the method is characterized in that N-acetylcysteine and quercetin are added into a culture medium used for culturing MSC cells, so that the MSC cells are stimulated to generate exosomes with anti-aging and anti-apoptosis effects. In addition, the exosome generated by stimulating the MSC through a culture mode of gradually reducing oxygen partial pressure further has an anti-aging effect; the adverse effects of acute oxidative stress, decline of multiplication capacity, unstable quality and the like in a low-oxygen state can be inhibited, and the activity of related components of cells and exosomes is not damaged. The method shows good anti-aging and anti-apoptosis effects in vitro, and a new thought is provided for treating aging diseases by the exosome in the future.

The invention relates to an implantable medical device and an implantable medical system, and relates to the technical field of medical instruments. An implantable medical device includes: a first tubular member; the far end of the second tubular component is connected with the near end of the first tubular component in a point connection manner; the near end of the sealing assembly is connected with the second tubular component, the far end of the sealing assembly axially extends in the direction away from the second tubular component so as to be at least partially contained in the first tubular cavity, the part, contained in the first tubular cavity, of the sealing assembly is of an annular structure and is provided with a free end, and the annular structure surrounds the longitudinal central axis of the first tubular component; the sealing assembly can be synchronously expanded or contracted along with the second tubular component, so that the outer wall of the part, contained in the first tubular cavity, of the sealing assembly is matched with the inner wall of the first tubular component to form a channel capable of being opened or closed. The implantable medical device can keep the blood flow smooth in the operation process, and adverse effects on the health of a patient due to blood flow blockage are prevented.

The present invention discloses a preparation method of Inonotus hispidus polysaccharide IHP-1aa: It is obtained by removing fat with ethanol, extracting with water and precipitating with ethanol, then removing proteins by the Sevage method, separating neutral polysaccharide components through a DEAE-52 cellulose column and a DEAE agarose gel column, and finally purifying with Sephadex G-100. The Inonotus hispidus polysaccharide has uniform purity and clear composition, and is a heteropolysaccharide composed of glucose, galactose, mannose, fucose and methylgalactose, with a molecular weight of 26.9 kDa. In vitro experiments show that it has no adverse effects on normal cells, can significantly stimulate macrophages RAW264.7 to secrete NO, IL-6 and TNF-α, has good immunomodulatory activity, and can be used for the development of immunomodulatory products.

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.

The invention discloses a preparation method of a composite spray for improving the hemostatic ability of a wound part, the composite spray comprises a liquid A and a liquid B. The liquid B is a sodium alginate aqueous solution, a preparation method of the solution A comprises the following steps: 1, dissolving a lipopeptide conjugate, cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidylserine and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2, preparing the mixed system into a precursor solution by utilizing a film hydration method; 3, adding calcium chloride into the precursor solution, and reacting in a dark place to obtain a solution A; a precursor solution is designed according to the function of natural platelets, the function of the precursor solution is equivalent to that of nano platelets, the precursor solution is matched with sodium alginate, adverse effects on a blood coagulation system caused by fibrin degradation, platelet activation capability reduction and the like of a wound part due to blood loss can be relieved in a targeted manner, and the preparation has the advantages of rapid hemostasis, good biological activity, no toxic or side effects and the like. And the wound healing is rapid.

Porous-based bone implants with the integration of Triply Periodic Minimal Surface, TPMS, porous architectures are designed to support the growth and proliferation of bone tissue, bone marrow, and capillaries. This disclosure intends to reduce the adverse effect of conventional implants such as bone resorption over time, which is called the “stress shielding effect”. The “stress shielding effect” is caused by the mismatch between the implant and natural bone stiffness. Triply Periodic Minimal Surface, TPMS, porous architectures exhibit interconnected pore features. The interconnection of the porous network allows the TPMS to have a higher permeability than that of other porous structures, leading to more favorable nutrient transport. In addition, many physical characteristics of the TPMS structures including surface-to-volume ratio, pore size, elastic modulus, and fluid behaviors can be controlled precisely through mathematical manipulation. As a result, TPMS-based implants could be physical features, which are vaned based on different bone regions. In other words, the medical implants may exhibit non-uniform or gradient physical features, which can match the characteristic of trabecular and cortical bones. Therefore, TPMS-based implants could adjust the features to mimic neighboring bone regions. As a result, we can achieve medical implants, which have superior mechanical and biological responses, resulting in optimal cell growth and better medical treatment.

The invention relates to a traditional Chinese medicine composition for treating allergic dermatitis. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of fried coix seeds, 5-35 parts of concha margaritifera, 1-30 parts of honeysuckle stems, 1-30 parts of smoked plums, 1-30 parts of fructus liquidambaris, 1-25 parts of fructus forsythiae, 1-25 parts of radix paeoniae rubra, 1-25 parts of raw sanguisorba officinalis, 1-25 parts of radix glehniae, 1-25 parts of radix ophiopogonis and 1-25 parts of raw radix polygonati officinalis. 1-25 parts by weight of talc and 1-25 parts by weight of lophatherum gracile. The traditional Chinese medicine composition has the effects of clearing heat, cooling blood without bitter cold, dispelling wind, eliminating dampness without hurting stomach, detoxifying, relieving itching and nourishing yin, is safe in clinical use, and has no adverse effect on liver and kidney.

To provide methods of treating a B-cell proliferative disorder.SOLUTION: The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20 / anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20 / anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.SELECTED DRAWING: None

The utility model relates to the technical field of medical instruments, in particular to a drainage tube orifice seepage prevention device which comprises a bowl-shaped seepage collection cavity, an annular pasting part is arranged at the edge of the seepage collection cavity, and the pasting part is coated with medical colloid to be pasted to a drainage tube orifice of a patient; a main pipe opening is formed in the seepage collecting cavity and allows the main drainage pipe to penetrate through, and an anti-seepage structure is arranged at the main pipe opening to prevent seepage liquid from leaking from the main pipe opening. An auxiliary drainage tube is arranged on the seepage collecting cavity, seepage at a drainage tube opening can be collected through the seepage collecting cavity and then drained away from the auxiliary drainage tube, and seepage leakage is avoided; the device body is extremely small, other wound treatment measures are not affected, meanwhile, liquid drainage is rapid, and the device cannot fall off due to dead weight caused by accumulation of a large amount of seepage; the problem of leakage of leakage liquid at the drainage tube opening can be effectively solved, and meanwhile, adverse effects on the main drainage tube are avoided; the main drainage tube can be supported, the main drainage tube is kept to be vertically inserted into the body of a patient, and the seepage risk caused by wound damage is reduced.

The present invention provides for the immediate or chronic administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to subjects to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration, and methods of dosing K ATP channel openers to achieve these outcomes and to reduce the incidence of adverse effects in treated individuals. Also provided are methods of co-administering K ATP channel openers with other drugs, e.g., in combination with growth hormone, to treat diseases in humans and animals, e.g., Prader-Willi Syndrome (PWS), Smith-Magenis Syndrome (SMS), etc.

The utility model relates to the technical field of radiotherapy, in particular to a heating bed board for radiotherapy, which comprises a first fiber layer, a non-metal heating structure layer, a foam board and a second fiber layer which are adhered and laid from top to bottom, and the non-metal heating structure layer is connected with a first metal electrode and a second metal electrode. The first metal electrode and the second metal electrode are arranged on the same side of the foam plate and are arranged in a non-treatment area. Current is led into the non-metal heating structure layer through the first metal electrode and the second metal electrode, so that the non-metal heating structure layer emits heat, the heating bed plate for radiotherapy is heated, the heating temperature can be controlled by controlling the size of the led-in current, and therefore effective control over the temperature is achieved, the somatosensory comfort degree of a patient during treatment is improved, and the radiotherapy effect is improved. And adverse effects on radiotherapy precision caused by movement of the body due to discomfort of the patient are avoided.

The invention discloses a knowledge graph embedding method based on negative sampling and weighting. The method comprises the following steps: acquiring a medicine data set; based on an embedded vector obtained by pre-training and a designed high-quality candidate negative sample set construction strategy, sampling a high-quality candidate negative sample set for all positive triads; according to the knowledge graph embedding model based on translation, calculating scoring function values of the triad and the negative triad corresponding to the triad; carrying out statistics on related frequency data in the data set, and calculating a frequency-based weight of each triple; according to the scoring function value and the weight, calculating the loss L of the triple set to obtain a final loss function of the training framework; optimizing a loss function of the training model by adopting a stochastic gradient descent method; and outputting a potential association relationship between the medicine and the disease and the symptom. According to the method, the negative sampling quality of the model is improved, the adverse effects of long-tail entities and relationships on model training are relieved by weighting the loss function, and the model training performance is improved.

Systems and methods for unipolar Pulse-Field Ablation (PFA) are disclosed for reducing spasm and / or other adverse nerves stimulation effects during delivery of PFA pulses. The system includes or is connected to one or more motion sensors to be placed at one or more regions of a patient's body for monitoring spasm thereat. The system includes a signal switch capable of selectively connecting a PFA energy generator to selected one or more of return electrode patches for delivery of PFA pulses and / or pacing signals through the selected electrode patches; and a processor that monitors motion sensed by the motion sensor(s) during delivery of the PFA pulses or pacing signals to identify nerve stimulation effects, such as spasm, to facilitate, based on the monitoring, selection of certain electrode patches by which the PFA pulses may be delivered without, or with reduced spasm or other adverse effects of excessive nerves stimulation.

[Problem] To provide a novel compound promising as a prodrug-type anticancer agent that exhibits a sufficient anticancer effect and is capable of reducing adverse effects. [Solution] A compound represented by general formula (I) or a pharmaceutically acceptable salt of the compound. Formula (I): Y-T-(X1)n

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Moreover, these properties also enable transport of the GPCR agonist fusion protein across the blood brain barrier and therefore allow treatment of neural disorders.